Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02068586|
Recruitment Status : Recruiting
First Posted : February 21, 2014
Last Update Posted : October 27, 2017
|Condition or disease||Intervention/treatment||Phase|
|Ciliary Body and Choroid Melanoma, Medium/Large Size Ciliary Body and Choroid Melanoma, Small Size Iris Melanoma Stage I Intraocular Melanoma Stage IIA Intraocular Melanoma Stage IIB Intraocular Melanoma Stage IIIA Intraocular Melanoma Stage IIIB Intraocular Melanoma Stage IIIC Intraocular Melanoma||Drug: Sunitinib Drug: Valproic Acid||Phase 2|
1) To assess the efficacy of adjuvant sunitinib malate or adjuvant valproic acid used for 6 months to improve overall survival (OS) at 2 years in patients with high-risk uveal melanoma.
- To assess the efficacy of adjuvant sunitinib malate and adjuvant valproic acid used for 6 months in preventing the development of distal metastases (relapse-free survival, RFS) in patients with high-risk uveal melanoma.
- To confirm the safety and tolerability of 6 months of adjuvant sunitinib and adjuvant valproic acid in patients with high-risk uveal melanoma.
- To assess the quality of life during the adjuvant treatment.
1) To determine whether blood myeloid-derived suppressor cells (MDSCs) concentration and other inflammatory cytokines correlates with OS and RFS.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive sunitinib malate orally (PO) daily for 6 months in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive valproic acid PO daily for 6 months in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||90 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Randomized Phase ll Study of Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma|
|Actual Study Start Date :||November 19, 2014|
|Estimated Primary Completion Date :||February 2019|
|Estimated Study Completion Date :||February 2020|
Patients receive sunitinib malate PO daily for 6 months in the absence of disease progression or unacceptable toxicity
Experimental: Valproic acid
Patients receive valproic acid PO daily for 6 months in the absence of disease progression or unacceptable toxicity
Drug: Valproic Acid
- Overall survival [ Time Frame: Time of definitive treatment of the primary tumor until death from any cause, assessed at 2 years ]
- Relapse-free survival [ Time Frame: Time of definitive treatment of the primary tumor until confirmed metastatic relapse or death from any cause, assessed at 2 years ]
- Tolerability [ Time Frame: 6 months ]Defined as the proportion of patients able to complete 6 months of treatment, including those who underwent dose reduction
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02068586
|Contact: Takami Sato, MD||215-955-8874|
|Contact: Melanoma Research Group||215-955-9980|
|United States, Pennsylvania|
|Sidney Kimmel Cancer Center at Thomas Jefferson University||Recruiting|
|Philadelphia, Pennsylvania, United States, 19107|
|Contact: Takami Sato, MD 215-955-8874|
|Contact: Melanoma Research Group|
|Sub-Investigator: Kendra Feeney, MD|
|Sub-Investigator: Michael Mastrangelo, MD|
|Sub-Investigator: Carol Shields, MD|
|Sub-Investigator: Jerry Shields, MD|
|Principal Investigator:||Takami Sato, MD||Thomas Jefferson University|